Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

No Impact of Corticosteroid Use During the Acute Phase on Persistent Symptoms Post-COVID-19

Abstract : Persistent COVID-19 symptoms may be related to residual inflammation, but no preventive treatment has been evaluated. This study aimed to analyze, in a prospective cohort, whether corticosteroid use in the acute phase of COVID-19 in hospitalized patients may reduce the risk of persistent COVID-19 symptoms. A total of 306 discharged patients, including 112 (36.6%) from the ICU, completed a structured face-to-face assessment 4 months after admission. Of these, 193 patients (63.1%) had at least one persistent symptom, mostly dyspnea (38.9%) and asthenia (37.6%). One-hundred and four patients have received corticosteroids. In multivariable adjusted regression analysis, corticosteroid use was not associated with the presence of at least one symptom (OR=1.00, 95% CI: 0.58-1.71, p=0.99) or with the number of persistent symptoms (p=0.74). Corticosteroid use remained ineffective when analyzing the ICU subpopulation separately. Our study suggests that corticosteroid use had no impact on persistent symptoms after COVID-19 in discharged patients.
Type de document :
Article dans une revue
Liste complète des métadonnées
Contributeur : Louise DESSAIVRE Connectez-vous pour contacter le contributeur
Soumis le : vendredi 2 septembre 2022 - 11:20:27
Dernière modification le : samedi 3 septembre 2022 - 03:32:04




Adrien Chan Sui Ko, Alexandre Candellier, Marie Mercier, Cedric Joseph, Hortense Carette, et al.. No Impact of Corticosteroid Use During the Acute Phase on Persistent Symptoms Post-COVID-19. International Journal of General Medicine, Dove Press ; Taylor & Francis, 2022, 15, pp.6645-6651. ⟨10.2147/IJGM.S367273⟩. ⟨hal-03767758⟩



Consultations de la notice